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Abstract In the setting of acute myocardial infarction,
hyperglycemia and acute insulin resistance may represent a
stress response to myocardial injury mainly related to acute
catecholamine release. By measuring glucose values and
insulin resistance (Homeostatic Model Assessment index—
HOMA), we evaluated in 356 non-diabetic patients with ST-
elevation myocardial infarction (STEMI) undergone
mechanical revascularization: (a) the acute glycometabolic
response by evaluating insulin resistance, glucose levels, and
their combination and (b) whether insulin resistance and
increased glucose values (and their combination) are able to
affect in-Intensive Cardiac Care Unit (ICCU) mortality and
complications. In the overall population, 226 (63.5%)
patients showed glucose values B140 mg/dl (group B),
while 130 patients had glucose values[140 mg/dl (group A)
(36.5%). Within group B, insulin resistance (as inferred by
positive HOMA index) was present in 125 patients (55.3%),
whereas 101 patients (44.7%) exhibited normal values of
HOMA index. Within group A, 109 patients (83.8%) were
insulin resistant, while 21 patients (16.2%) had normal val-
ues of HOMA index. At multivariable analysis, glucose
values were independently associated with in-ICCU mor-
tality (OR: 7.387; 95% CI 2.701–20.201; P \ 0.001) and
complications (OR: 1.786; 95% CI 1.089–2.928; P =
0.022). In the early phase of STEMI, the acute glycometa-
bolic response to stress is heterogeneous (ranging from no
insulin resistance to glucose levels[140 mg/dl and, finally,
to the combination of increased glucose values and insulin
resistance). Increased glucose values are stronger prognostic
factors since they are independently associated with in-
ICCU mortality and complications.
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Introduction
In the setting of acute myocardial infarction [1], hyper-
glycemia is not simply a marker of pre-existing diabetes or
glucose intolerance but it may represent a stress response to
myocardial injury mainly related to acute catecholamine
release [2, 3].
In patients with ST-elevation myocardial infarction
(STEMI), hyperglycemia is common and, though fre-
quently untreated, associated with an increased risk of
death [4–7]. In these patients, increased glucose values
hold a prognostic role when measured not only on admis-
sion [4] but also throughout hospital stay [8–10]. We
recently observed [11] that glucose serum levels, measured
after mechanical revascularization, were independent pre-
dictors of in-hospital mortality in STEMI patients without
previously known diabetes undergone primary percutane-
ous coronary intervention (PCI).
Insulin resistance is known to be part of the glycometa-
bolic response to stress, but few studies assessed the role of
insulin resistance, evaluated by means of Homeostatic
Model Assessment (HOOMA index), in the early phase of
acute myocardial infarction [12, 13]. In non-diabetic STEMI
patients undergone PCI, we reported that insulin resistance,
as assessed by HOMA index, is quite common and helps
in the early risk stratification, since it represents an
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independent predictor for in-hospital mortality [14]. Thus,
the glycometabolic response to acute myocardial ischemia
appears to be quite complex and, so far, poorly understood.
In critically ill patients [15], it has been reported that
insulin resistance may develop in the absence of hyper-
glycemia probably thanks to the fact that increased
endogenous production of insulin is responsible for normal
glucose values [15].
In the present investigation, performed in consecutive
STEMI patients undergone mechanical revascularization
and without previously known diabetes, we investigated
the acute glycometabolic response in the early phase by
evaluating insulin resistance, as assessed by HOMA index,
glucose levels, and their combination. Furthermore, we
investigated the different role(s) (if any) of insulin resis-
tance and increased glucose values (both isolated and in
combination) in affecting in-Intensive Cardiac Care Unit
(ICCU) mortality and adverse events (acute pulmonary
edema and arrhythmias).
Methods
Study population
From June 30, 2008, to June 30, 2009, 356 consecutive
patients with STEMI (within 12 h from symptoms’ onset)
and without previously known diabetes were admitted to
our ICCU, which is located at a tertiary center and pro-
spectively enrolled in our study. The Florence health dis-
trict (approximately 800,000 inhabitants—Metropolitan
Florence area) includes five community hospitals and one
teaching hospital (Azienda Ospedaliero-Universitaria Car-
eggi). In the latter, a Heart and Vessel Department runs
three ICCUs and operates high volume programs for PCI.
Regarding cardiac emergencies, Careggi hospital is also the
referring center for four community hospitals (the furthest
being 50 km away from Careggi), located in the so-called
area Vasta. In our hospital, in Florence, the reperfusion
strategy of STEMI patients is represented by primary PCI
[16–18]. STEMI patients are first evaluated by the Medical
Emergency System staff in the pre-hospital setting and then
directly admitted to the catheterization laboratory or
transferred to it after a rapid stabilization in the first aid.
After primary PCI, they are admitted to our ICCU.
A successful procedure was defined as an infarct artery
stenosis \20% associated with TIMI (Thrombolysis in
Myocardial Infarction) grade 3 flow. Failure PCI was
defined as resulting in TIMI grade 0–2 flow, regardless the
residual stenosis [19].
The diagnosis of STEMI was based on the criteria of the
American College of Cardiology/American Heart Associ-
ation [20].
Blood samples were driven on ICCU admission, after
mechanical revascularization, in a fasting state. The fol-
lowing parameters were measured: glucose (mg/dl), tro-
ponin I (ng/ml), insulin (mU/l), uric acid (mg/dl), high-
sensitivity C-reactive protein (mg/dl) (normal values \9),
NT-pro-brain natriuretic peptide (NT-BNP) (pg/ml) [16],
and fibrinogen (mg/dl). Blood samples were collected
bedside and analyzed at the Central Laboratory in our
Azienda Ospedaliera Careggi by routine laboratory
methods. Plasma glucose levels were measured with the
glucose-oxidase method [21] and plasma insulin levels
with a double antibody RIA method [22]. All biomarkers
were measured according to the assay guidelines provided
by the manufacturers of the instruments and assay kits:
cTnI, Dade Behring Stratus CS and Dimension RxL; NT-
proBNP, Roche Elecsys 2010; hsCRP, Dade Behring
Dimension. Creatinine (mg/dl) was also measured in order
to calculate glomerular filtration rate (ml/min/1.73 m2)
[23].
The study population was divided in two subgroups
according to glycemia on ICCU admission: group A (gly-
cemia [ 140 mg/dl) and group B (Glycemia B 140 mg/
dl). The cut-off of glycemia 140 mg/dl was chosen
according to guidelines [4]. Within each subgroup, patients
were subdivided according the presence or absence of
insulin resistance as inferred by positive HOMA index.
Transthoracic 2-dimensional echocardiography (per-
formed using a Toshiba machine model SSA 270 HG
equipped with a 2.5-or 3.75-MHz transducer) was per-
formed on ICCU admission in order to measure left ven-
tricular ejection fraction (LVEF, according to Teicholz’s
method [24]); wall cinetic alterations and the presence of
valvular disease and of pericardial fluid were also
investigated.
In-ICCU mortality and in-ICCU complications (acute
pulmonary edema and arrhythmias) were considered as
outcomes.
Definition of insulin resistance
Criteria used for the definition of insulin resistance are in
accordance with the recently published guidelines pro-
posed by the European Group of the study of Insulin
Resistance (EGIR) [25, 26]. HOMA was calculated
according to the following formula: {[fasting insulin (mi-
croU/ml)] 9 [fasting glucose (mmol/l)]}/22.5 [27]. Sub-
jects whose values exceeded the sex-specific 75th
percentile (i.e., 1.80 for women and 2.12 for men) were
considered to have insulin resistance (HOMA-IR) [14, 28].
The study protocol was in accordance with the Decla-
ration of Helsinki and approved by the local Ethics Com-
mittee. Informed consent was obtained in all patients
before enrollment.
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Statistical analysis
Data have been entered in a dedicated database and pro-
cessed by means of SPSS 13.0 statistical package (SPSS
Inc. Chicago, IL). A two-tailed P value \ 0.05 was con-
sidered statistically significant. Data of glycemia sub-
groups are reported as frequencies (percentages) and
medians (25–75th percentile) and were analyzed by
Fisher’s exact test for categorical variables with any field
including \6 patients, or v2 test for the other categorical
variables, and Mann–Whitney U test (continuous variables
that resulted almost all non-normally distributed at one-
sample Kolmogorov–Smirnov test). Multivariable logistic
regression analyses were performed in an explorative
manner to find predictors for both mortality and compli-
cations. For each outcome, a backward stepwise procedure
was performed using P [ 0.10 of the likelihood ratio test
for exclusion.
Results
Clinical characteristics and angiographic data
Table 1 shows the clinical characteristics of STEMI
patients included in the study. In the overall population,
226 (63.5%) patients showed glucose values B140 mg/dl
(group B), while 130 patients had glucose values
[140 mg/dl (group A) (36.5%). Within group B, insulin
resistance (as inferred by positive HOMA index) was
present in 125 patients (55.3%), whereas 101 patients
(44.7%) exhibited normal values of HOMA index. Within
group A, 109 patients (83.8%) were insulin resistant,
while 21 patients (16.2%) had normal values of HOMA
index. In group B, patients with insulin resistance showed
higher values of BMI and higher incidence of dyslipide-
mia when compared to those without (P = 0.004 and
P = 0.014, respectively). No difference was detectable
Table 1 Clinical characteristics of patients included in the study
Variable frequency
(%) or median
(25–75th
percentile)
Glycemia [ 140 mg/dl (n = 130)
Group A
Glycemia B 140 mg/dl (n = 226)
Group B
No insulin
resistance
(n = 21)
Insulin resistance
(n = 109)
P
Fisher’s exact
test or Mann–
Whitney
U test
No insulin
resistance
(n = 101)
Insulin resistance
(n = 125)
P
Fisher’s exact
test or Mann–
Whitney
U test
Females/males 6/15 (28.6/71.4%) 35/74 (32.1/67.9%) 1 30/71 (29.7/70.3%) 22/103 (17.6/82.4%) 0.039
Age (years) 65 (56–80) 70 (60–78) 0.127 64 (56–76) 61 (54–70) 0.420
BMI (kg/m2) 23.5 (22.5–25.6) 25.8 (24.2–28.0) \0.001 24.9 (22.8–27.1) 26.6 (25.0–28.7) 0.004
Hypertension 10 (47.6%) 53 (48.6%) 1 38 (37.6%) 43 (34.4%) 0.676
Dyslipidemia 9 (42.9%) 46 (42.2%) 1 31 (30.7%) 59 (47.2%) 0.014
Smoke
No smoke 4 (19.0%) 54 (49.5%) 0.015 31 (30.7%) 38 (30.4%) 1
Previous smoke/
ever smoke
17 (81.0%) 55 (50.5%) 70 (69.3%) 87 (69.6%)
Comorbidities 2 (9.5%) 8 (7.3%) 0.664 2 (2.0%) 4 (3.2%) 0.694
Renal failure 0 5 (4.6%) 1.000 1 (1.0%) 4 (3.2%) 0.384
COPD 2 (9.5%) 7 (6.4%) 0.638 8 (7.9%) 6 (4.8%) 0.409
Previous MI 4 (19.0%) 16 (14.7%) 0.741 17 (16.8%) 11 (8.8%) 0.103
Killip class
I 14 (66.7%) 83 (76.1%) 0.597 91 (90.1%) 110 (88.0%) 0.692
II 1 (4.8%) 8 (7.3%) 6 (5.9%) 12 (9.6%)
III 1 (4.8%) 4 (3.7%) 1 (1.0%) 1 (0.8%)
IV 5 (23.8%) 14 (12.8%) 3 (3.0%) 2 (1.6%)
AMI location
Inferior 8 (38.1%) 40 (36.7%) 0.755 44 (43.6%) 53 (42.4%) 0.721
Lateral 2 (9.5%) 6 (5.5%) 7 (6.9%) 6 (4.8%)
Anterior 11 (52.4%) 63 (57.8%) 50 (49.5%) 66 (52.8%)
LVEF (%) 40 (32–46) 40 (35–48) 0.769 45 (38–52) 45 (39–52) 0.701
BMI body mass index, COPD chronic obstructive pulmonary disease, MI myocardial infarction, AMI acute myocardial infarction, LVEF left
ventricular ejection fraction
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between the two subgroups with regard to myocardial
infarction (MI) location, Killip class, and left ventricular
ejection fraction. In group A, patients with insulin resis-
tance showed higher values of BMI and lower incidence
of previous smokers/ever smokers (P \ 0.001 and
P = 0.015, respectively). MI location, Killip class, and
left ventricular ejection fraction did not significantly differ
between the two subgroups.
Table 2 depicts angiographic data in our population.
No differences were detectable with regard to severity
of coronary artery disease and the incidence of PCI
failure.
In the early phase of STEMI, patients without previously
known diabetes showed different behaviors in regard to the
glycemic response to acute stress. These imply increased
glucose values associated or not with insulin resistance.
The latter was more common in patients with higher BMI
values and a higher incidence of dyslipidemia.
Biochemical data
Biochemical data are shown in Table 3. In group B,
patients with insulin resistance showed higher values of
NT-pro-BNP, lactic acid, and Tn I (P = 0.012, P = 0.003,
and P = 0.015, respectively). In group A, no differences
were detectable in the considered variables between
patients with insulin resistance and those without.
Among patients with glucose values \140 mg/dl, those
who showed insulin resistance had a higher infarct size (as
indicated by peak Tn I).
Overall complications were as follows: 35 patients had
arrhythmias (atrial fibrillation/atrial flutter: 22; ventricular
tachycardia: 8; and AV block: 5) while 20 patients pul-
monary edema and 24 patients cardiogenic shock. Patients
with glycemia[140 mg/dl and insulin resistance showed a
higher incidence of in-ICCU complications when compared
to patients with glucose values \140 mg/dl and insulin
resistance (34/109—31.2% vs. 25/125 —20.7%; P =
0.025). In-ICCU mortality rate was significantly higher in
patients with glycemia [140 mg/dl and insulin resistance
when compared to those with glucose values B140 mg/dl
and insulin resistance (7/109—6.4% vs. 0; P = 0.004).
Patients with glycemia[140 mg/dl and no insulin resistance
exhibited a higher mortality rate when compared to patients
with glucose values B140 mg/dl and no insulin resistance (4/
21—19.0% vs. 1—1.0%; P = 0.003).
As shown in Table 4, among patients without insulin
resistance, group A showed a higher Killip class
(P \ 0.001), higher values of HbA1c (P = 0.036), lactic
acid (P = 0.004), and a higher mortality rate (P = 0.003).
Among patients with insulin resistance, group A was older
(P \ 0.001), showed a higher Killip class (P \ 0.001) and
a lower LVEF (P \ 0.001), and had higher values of
HbA1c (P \ 0.001), NT-pro-BNP (P \ 0.001), lactic acid
Table 2 Angiographic data
Variable frequency
(%) or median
(25–75th
percentile)
Glycemia [ 140 mg/dl (n = 130)
Group A
Glycemia B 140 mg/dl (n = 226)
Group B
No insulin
resistance
(n = 21)
Insulin resistance
HOMA
positive ([1.80 donne,
[2.18 uomini)
(n = 109)
P
Fisher’s exact test
or Mann–
Whitney U test
No insulin
resistance
(n = 101)
Insulin resistance
HOMA
positive ([1.80 donne,
[2.18 uomini)
(n = 125)
P
Fisher’s exact test
or Mann–
Whitney U test
Coronary artery disease
No disease 0 0 0.622 1 (1.0%) 0 0.713
1-vessel 10 (47.6%) 40 (37.0%) 47 (46.5%) 59 (47.2%)
2-vessel 6 (28.6%) 33 (30.6%) 33 (32.7%) 39 (31.2%)
3-vessel 5 (23.8%) 35 (32.4%) 20 (19.8%) 27 (21.6%)
CABG 0 1 (0.9%) 1 0 1 (0.8%) 1
IRA
RCA 7 (36.8%) 33 (30.8%) 0.016 38 (38.8%) 38 (30.4%) 0.270
CX 1 (5.3%) 8 (7.5%) 10 (10.2%) 20 (16.0%)
DA 9 (47.4%) 65 (60.7%) 49 (50.0%) 67 (53.6%)
Left main 2 (10.5%) 0 0 0
CABG 0 1 (1%) 0 0
PCI failure 2 (9.5%) 9 (8.4%) 1 1 (1.0%) 4 (3.2%) 0.384
CABG coronary artery by-pass graft, IRA infarct-related artery, RCA right coronary artery, CX circumflex artery, DA descending artery, PCI
percutaneous coronary intervention
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(P \ 0.001), peak Tn I (P = 0.021), and C-reactive protein
(P = 0.003), lower values of eGFR (P \ 0.001), and a
higher mortality rate (P = 0.004).
Multivariate analysis
At backward logistic regression analysis, the following
variables resulted independent predictors for in-ICCU com-
plications (when corrected for HOMA index): NT-pro-BNP
values (OR: 1.012; 95% CI 1.004–1.020; P = 0.003), Tn I
(OR: 1.003; 95% CI 1.001–1.004; P = 0.022), and glucose
values (OR: 7.387; 95% CI 2.701–20.201; P \ 0.001).
Hosmer and Lemeshow test: 2.516; P = 0.961.
At backward logistic regression analysis, the following
variables resulted independent predictors for in-ICCU mor-
tality (when corrected for HOMA index): Killip class (OR:
1.456; 95% CI 1.075–1.971; P = 0.015), ejection fraction
(OR: 0.965; 95% CI 0.936–0.994; P = 0.018), and glucose
values (OR: 1.786; 95% CI 1.089–2.928; P = 0.022). Hos-
mer and Lemeshow test: 9.318; P = 0.316.
When assessing the prognostic impact of the glycemic
response to stress, only glucose values were independent
predictors for both in-ICCU complications and mortality.
Discussion
The main finding of the present investigation is that, in
STEMI patients without previously known diabetes
undergone mechanical revascularization, the acute glyco-
metabolic response to stress is, in the early phase, complex
and quite heterogeneous (ranging from no insulin resis-
tance to glucose levels [140 mg/dl and, finally, to the
combination of increased glucose values and insulin
resistance). In fact, in our series, insulin resistance despite
glucose levels B140 mg/dl was detectable in about one-
third of the entire population. In this subgroup, insulin
resistance can be related not only to pre-existing conditions
(such as dyslipidemia and increased BMI) but also to
‘‘factors’’ strictly related to the acute phase: increased
infarct size (as indicated by higher Tn I levels) and a more
severe systemic derangement (as indicated by increased
NT-pro-BNP levels and higher lactic acid values).
Our data are in agreement with previous studies per-
formed in non-critically ill patients. In these investigations,
isolated insulin resistance without over hyperglycemia was
associated with increased inflammation, coagulation
abnormalities [29–31], and severity of illness [32].
In presence of insulin resistance [33], the ischemic
myocardium is forced to utilize free fatty acids (FFA) more
than glucose for an energy source because myocardial
glucose uptake is impaired and, in this setting, it is more
prone to a metabolic crisis (since the hypoxic myocardium
becomes less energy efficient). We recently [14] showed
that insulin resistance (assessed by HOMA index) repre-
sents an independent predictor for early mortality. More
recently, Garcia et al. [34] observed that hyperinsulinism
was the most important factor associated with the
Table 3 Biochemical data
Variable
median
(25–75th
percentile)
Glycemia [ 140 mg/dl (n = 130)
Group A
Glycemia \/=140 mg/dl (n = 226)
Group B
No insulin
resistance
(n = 21)
Insulin resistance
(n = 109)
P
Fisher’s exact test
or Mann–
Whitney U test
No insulin
resistance
(n = 101)
Insulin resistance
(n = 125)
P
Fisher’s exact test
or Mann–
Whitney U test
HbA1c (%) 6.0 (5.6–6.4) 6.0 (5.7–6.6) 0.737 5.7 (5.4–6.1) 5.8 (5.5–6.0) 0.622
NT-pro-BNP
(pg/ml)
1,984 (1,022–7,646) 1,735 (595–4,061) 0.395 760 (294–738) 1,373 (562–2,461) 0.012
Lactic acid 2.0 (1.1–3.6) 2.2 (1.5–2.7) 0.865 1.1 (0.8–1.8) 1.4 (1.1–1.9) 0.003
C-reactive
protein
positivity
13 (68.4%) 65 (63.1%) 0.797 57 (60.6%) 52 (43.3%) 0.013
Peak Tn I
(ng/ml)
88.3 (27.7–425.5) 115.6 (64.5–224.0) 0.972 58.8 (24.1–138.3) 83.8 (43.0–173) 0.015
eGFR ml/
min/1.73 m2
86.2 (70.2–104.2) 74.8 (56.4–92.2) 0.902 87.3 (73.1–107.1) 91.3 (73.3–104.9) 0.073
Uric acid
(mg/dl)
5.2 (4.2–6.2) 5.7 (4.8–6.8) 0.128 5.3 (4.2–6.2) 5.4 (4.5–6.5) 0.184
Fibrinogen
(mg/dl)
404 (330–535) 379 (320–486) 0.321 383 (329–434) 382 (324–448) 0.676
NT-pro-BNP N terminal-pro-brain natriuretic peptide, Tn I troponin I, eGFR estimated glomerular filtration rate
Acta Diabetol
123
occurrence of new cardiovascular events at long-term fol-
low-up in Colombian patients with acute myocardial
infarction, thus empathizing the prognostic role of insulin
resistance even at long term.
In acute coronary syndromes, insulin-resistant patients
are known to be more prone to hyperglycemia [35, 36]. In
our series, glucose values (when corrected for HOMA
index) are independently associated with in-ICCU
Table 4 Comparison between patients with insulin resistance and those without
Variable median
(25–75th percentile)
No insulin resistance (n = 122) Insulin resistance (n = 234)
Glycemia [ 140 mg/
dl (n = 21)
Group A
Glycemia B 140 mg/
dl (n = 101)
Group B
P value Glycemia [ 140 mg/
dl (n = 109)
Group A
Glycemia \/
=140 mg/dl
(n = 125)
Group B
P value
Clinical data
Females/males 15/6
71.4/28.6
71/30
70.3/29.7
0.918 74/35
67.9/32.1
103/22
82.4/17.6
0.010
Age (years) 65 (56–80) 64 (56–76) 0.679 70 (60–78) 61 (54–70) \0.001
BMI(kg/m2) 23.5 (22.5–25.6) 24.9 (22.8–27.1) 0.397 25.8 (24.2–28.0) 26.6 (25.0–28.7) 0.051
Killip class
I–II 15 (71.5%) 97 (96.0%) \0.001 91 (83.5%) 122 (97.6%) \0.001
III–IV 6 (28.5%) 4 (4.0%) 18 (16.5%) 3 (2.4%)
AMI location 0.857 0.671
Inferior 8 (38.1%) 44 (43.6%) 40 (36.7%) 53 (42.4%)
Lateral 2 (9.5%) 7 (6.9%) 6 (5.5%) 6 (4.8%)
Anterior 11 (52.4%) 50 (49.5%) 63 (57.8%) 66 (52.8%)
LVEF (%) 40 (32–46) 45 (38–52) 0.008 40 (35–48) 45 (38–52) \0.001
Coronary artery disease 0.932 0.158
No disease 0 (0.0%) 1 (1.0%) – –
1-vessel 10 (47.6%) 47 (46.5%) 41 (37.6%) 59 (47.2%)
2-vessel 6 (28.6%) 33 (32.7%) 33 (30.3%) 39 (31.2%)
3-vessel 5 (23.8%) 20 (19.8%) 35 (32.1%) 27 (21.6%)
PCI failure 2 (9.5%) 1 (1.0%) 0.076* 9 (8.4%) 4 (3.2%) 0.085
Biochemical data
HbA1c, median (IR),
(%)
6.0 (5.6–6.4) 5.7 (5.4–6.1) 0.036 6.0 (5.7–6.6) 5.8 (5.5–6.0) \0.001
NT-pro-BNP, median
(IR), (pg/ml)
1,984 (1,022–7,646) 760 (294–738) 0.051 1,735 (595–4,061) 1,373 (562–2,461) \0.001
Lactic acid, median
(IR), mmol/l
2.0 (1.1–3.6) 1.1 (0.8–1.8) 0.004 2.2 (1.5–2.7) 1.4 (1.1–1.9) \0.001
C-reactive protein
positivity, n (%)
13/19 (68.4%) 57/94 (60.6%) 0.524 65/103 (63.1%) 52/120 (43.3%) 0.003
Peak Tn I, median (IR),
(ng/ml)
88.3 (27.7–425.5) 58.8 (24.1–138.3) 0.062 115.6 (64.5–224.0) 83.8 (43.0–173) 0.021
eGFR, median (IR), (ml/
min/1.73 m2)
86.2 (70.2–104.2) 87.3 (73.1–107.1) 0.724 74.8 (56.4–92.2) 91.3 (73.3–104.9) \0.001
Uric acid, median (IR),
(mg/dl)
5.2 (4.2–6.2) 5.3 (4.2–6.2) 0.833 5.7 (4.8–6.8) 5.4 (4.5–6.5) 0.367
Fibrinogen, median (IR),
(mg/dl)
404 (330–535) 383 (329–434) 0.248 379 (320–486) 382 (324–448) 0.592
Mortality, n (%) 4 (19.0) 1 (1.0) 0.003* 7 (6.4) 0 (0.0) 0.004*
IR interquartile range (25–75th percentile)
BMI body mass index, AMI acute myocardial infarction, LVEF left ventricular ejection fraction, PCI percutaneous coronary intervention, Hb A1c
glycated hemoglobin, NT-pro-BNP N terminal-pro-brain natriuretic peptide, eGFR estimated glomerular filtration rate
* Fisher’s exact test
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mortality (thus confirming previous data by others and us)
[4–11] and with in-ICCU complications.
The complexity of the glycometabolic response to stress
during acute myocardial infarction, as well as the scarcity
of data on this topic, can be inferred by still existing
controversies on how to manage increased glucose values
in patients with acute coronary syndromes. According to
recent guidelines [4], it is reasonable to consider intensive
glucose control in patients with significant hyperglycemia
(that is plasma glucose [180 mg/dl), but strategies for the
management of patients with milder degrees of hypergly-
cemia are far to be elucidated. We recently [37] observed
that in non-diabetic STEMI patients, the poorer in-hospital
glucose control was associated with higher mortality; peak
glycemia [180 mg/dl was associated with the highest
mortality, whereas patients with peak glycemia comprised
between 140 and 180 mg/dl exhibited intermediate mor-
tality rates. No recommendation is so far available on
whether (and, if so, how) to treat STEMI insulin-resistant
patients.
In a recent paper [27] we observed that, in the early
phase of STEMI patients without previously known dia-
betes, insulin secretion and acute insulin resistance can be
strictly related to BMI, while the degree of inflammatory
activation, myocardial damage, and age are able to influ-
ence glucose values.
The results of the present investigation further extend
previous findings documenting that glucose values have a
stronger prognostic role for early death, since only glucose
values (and not HOMA index positivity) were indepen-
dently associated with in-ICCU mortality.
Limitations
A possible limitation of our study may be represented by
the methodology of HOMA index approach in assessment
of insulin resistance, since it was proposed mainly for
stable patients. However, Holzinger et al. [38] in a group of
30 critically ill medical patients (continuously sedated and
ventilated) documented that HOMA index, though indi-
cating insulin resistance, did not correlated with the M-
values and concluded that the euglycemic hyperinsuline-
mic clamp, which reflects stimulated insulin sensitivity,
remains the gold standard technique for quantifying insulin
resistance in critically ill patients. However, euglycemic
hyperinsulinemic clamp is time-consuming, labor intensive
and requires an experienced operator to manage the tech-
nical difficulties, so it is known to be not appropriate for
routine clinical applications [39]. On the other hand,
HOMA index, which reflects basal insulin sensitivity and
responsiveness, has been recently used to estimate insulin
resistance in critically ill patients with acute renal failure
[40].
In conclusion, according to our data, in STEMI patients
without previously known diabetes undergone mechanical
revascularization, the acute glycometabolic response to
stress in the early phase is heterogeneous (ranging from no
insulin resistance to glucose levels [140 mg/dl and,
finally, to the combination of increased glucose values and
insulin resistance). Increased glucose values are stronger
prognostic factors since they are independently associated
with in-ICCU mortality and complications. Further studies
are needed to better elucidate the role of insulin resistance
alone and to assess whether insulin-resistant STEMI
patients deserve a peculiar therapeutic strategy despite
normal glucose values.
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